
Feature|Videos|January 9, 2025
Capacity and Surge Response Leading Into a State of Readiness
Sustaining pandemic readiness requires investment in workforce, infrastructure, and scalable manufacturing practices.
Advertisement
Episodes in this series

Declining pandemic readiness is cause for concern; as such, the panelists highlight the importance of maintaining manufacturing capacity, a skilled workforce, and robust health infrastructure. Sustainable practices, including leveraging flu vaccine systems, are recommended for better future preparedness.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Samsung Biologics Bolsters US Manufacturing Network with GSK Facility Buy
2
Novel Delivery Approaches of Biopharmaceuticals 2025
3
GSK and CAMP4 Partner to Advance RNA-Targeting Therapeutics
4
EMA Director Highlights Agency Achievements in 2025
5



